Drugs / Vibecotamab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02730312 | Aug 2016 → Sep 2021 | B-cell acute lymphoblastic leukemia, CD4+/CD56+ hematodermic neoplasm, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive | Xencor, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07538206 | Apr 2026 → Apr 2031 expected | head and neck cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05285813 | May 2022 → May 2026 | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vibecotamab | “Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently binds both CD3 and CD123 to recruit cytotoxic T cells to kill CD123+ tumor cells.” PMID 37647601 ↗ Nov 2023 |
| Known as | XmAb14045 | “Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently binds both CD3 and CD123 to recruit cytotoxic T cells to kill CD123+ tumor cells.” PMID 37647601 ↗ Nov 2023 |
| Action | Deplete | “recruit cytotoxic T cells to kill CD123+ tumor cells” PMID 37647601 ↗ Nov 2023 |
| Modality | Monoclonal antibody | — CHEMBL4298131 ↗ |
| Route | Intravenous | “Administered IV weekly up to 8 weeks” NCT02730312 ↗ |